How Do You Solve A Problem Like Biopsy In Alcohol-Associated Liver Disease?
Biopsy results may be informative in early phase trials, but costs have limited their use in US clinical practice, raising questions about whether procedure should be required in drug development.
You may also be interested in...
Alcoholism is not a requirement to develop condition, but often is assumed of patients, so researchers offer name change to avoid stereotypes.
As Gilead’s ASK1 inhibitor nears Phase III, Intercept may be plagued by slower-than-expected enrollment of its Phase III trial for Ocaliva. A recent Biomedtracker survey finds liver docs may be more positively inclined toward the Gilead candidate.
Emails reveal company wanted timelines and approval commitments from FDA toward the end of the eteplirsen review, saying it might not be able to continue studies; at the same time, Sarepta was telling investors it had 12 months of cash on hand.